Literature DB >> 8624220

Citicoline improves verbal memory in aging.

P A Spiers1, D Myers, G S Hochanadel, H R Lieberman, R J Wurtman.   

Abstract

OBJECTIVE: To test the verbal memory of older volunteers given citicoline.
DESIGN: A randomized, double-blind, placebo-controlled, parallel group design was employed in the initial study. After data analysis, a subgroup was identified whose members had relatively inefficient memories. These subjects were recruited for a second study that used a crossover design. The subjects took either placebo or citicoline, 1000 mg/d, for 3 months in the initial study. In the crossover study, subjects took both placebo and citicoline, 2000 mg/d, each for 2 months.
SUBJECTS: The subjects were 47 female and 48 male volunteers 50 to 85 years old. They were screened for dementia, memory disorders, and other neurological problems. Of the subjects with relatively inefficient memories, 32 participated in the crossover study. MAIN OUTCOME MEASURE: Verbal memory was tested at each study visit using a logical memory passage. Plasma choline concentrations were measured at baseline; at days 30, 60, and 90 in the initial study; and at day 60 of each treatment condition in the crossover study. Plasma choline concentrations and memory scores were analyzed using repeated-measures analysis of variance and covariance, followed by planned comparisons when appropriate.
RESULTS: In the initial study, citicoline therapy improved delayed recall on logical memory only for the subjects with relatively inefficient memories. In the crossover study, the higher dosage of citicoline was clearly associated with improved immediate and delayed logical memory.
CONCLUSIONS: Citicoline therapy improved verbal memory functioning in older individuals with relatively inefficient memories. Citicoline may prove effective in treating age-related cognitive decline that may be the precursor of dementia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624220     DOI: 10.1001/archneur.1996.00550050071026

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  19 in total

Review 1.  Possible Benefit and Validity of Supplements for Alcohol Use Disorder.

Authors:  Seungwoo Kang; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2019-03-14       Impact factor: 3.455

Review 2.  Utility of nutraceutical products marketed for cognitive and memory enhancement.

Authors:  Graham J McDougall; Vonnette Austin-Wells; Teena Zimmerman
Journal:  J Holist Nurs       Date:  2005-12

Review 3.  Defining and measuring functional recovery from depression.

Authors:  Tracy L Greer; Benji T Kurian; Madhukar H Trivedi
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 4.  Choline and betaine in health and disease.

Authors:  Per Magne Ueland
Journal:  J Inherit Metab Dis       Date:  2010-05-06       Impact factor: 4.982

Review 5.  Citicoline in addictive disorders: a review of the literature.

Authors:  Nicholas D Wignall; E Sherwood Brown
Journal:  Am J Drug Alcohol Abuse       Date:  2014-06-20       Impact factor: 3.829

6.  Lower plasma choline levels are associated with sleepiness symptoms.

Authors:  Victoria M Pak; Feng Dai; Brendan T Keenan; Nalaka S Gooneratne; Allan I Pack
Journal:  Sleep Med       Date:  2017-10-26       Impact factor: 3.492

7.  Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers.

Authors:  Stephanie C Licata; David M Penetar; Caitlin Ravichandran; John Rodolico; Christopher Palmer; Jeff Berko; Thomas Geaghan; Alison Looby; Erica Peters; Elizabeth Ryan; Perry F Renshaw; Scott E Lukas
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

8.  Randomized, double-blind, placebo-controlled clinical trial of choline supplementation in school-aged children with fetal alcohol spectrum disorders.

Authors:  Tanya T Nguyen; Rashmi D Risbud; Sarah N Mattson; Christina D Chambers; Jennifer D Thomas
Journal:  Am J Clin Nutr       Date:  2016-11-02       Impact factor: 7.045

9.  Phospholipid biosynthetic enzymes in human brain.

Authors:  B M Ross; A Moszczynska; J K Blusztajn; A Sherwin; A Lozano; S J Kish
Journal:  Lipids       Date:  1997-04       Impact factor: 1.880

10.  Souvenaid®: a new approach to management of early Alzheimer's disease.

Authors:  C W Ritchie; J Bajwa; G Coleman; K Hope; R W Jones; M Lawton; M Marven; P Passmore
Journal:  J Nutr Health Aging       Date:  2014-03       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.